

ABSTRACT OF THE DISCLOSURE

Methods ~~and compositions~~ for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The ~~compositions~~ <sup>methods</sup> comprise ~~a compound having a~~ <sup>administering the</sup> pharmacological selectivity of serotonin ( $K_i$ )/norepinephrine ( $K_i$ ) of at least about 5000. ~~Examples~~ of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

457  
6/12/02

257  
6/12/02